Eli Lilly Reports post-marketing Data for Osimertinib in COPD

Eli Lilly today announced post-marketing results for osimertinib in patients with COPD. The study demonstrated that osimertinib achieves clinical remission compared to standard of care or placebo. These results provide important insights into the treatment of COPD and support the continued development of osimertinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.